HighTide Therapeutics, Inc. (HKG:2511)

Market Cap	1.47B -8.9%
Revenue (ttm)	n/a
Net Income	-272.60M
EPS	-0.57
Shares Out	571.33M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	54,500
Open	2.320
Previous Close	2.570
Day's Range	2.320 - 2.690
52-Week Range	1.800 - 4.720
Beta	-0.27
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 25, 2026

About HighTide Therapeutics

HighTide Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies to treat patients with chronic metabolic and liver diseases in Mainland China. Its lead drug candidate is HTD1801, which is in phase III clinical trial to treat type 2 diabetes mellitus (T2DM); in phase I clinical trial to treat gradual loss of kidney function over time; phase IIb for the treatment of pathogenetic complexity and heterogeneity; phase I to treat obesity; and phase II for the treatment of chronic cholestatic liver disea...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 51
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2511

Financial Performance

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 10, 2026

Data Sources Report a data error